Swiss Startup Biocartis Targets Decentralized MDx Market

Biocartis' platform, acquired from Philips earlier in the year, is meant to address a market that doesn't need large numbers of test batches being run on a regular basis.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories